Welcome to our dedicated page for Nurix Therapeutics SEC filings (Ticker: NRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nurix Therapeutics, Inc. (Nasdaq: NRIX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer focused on targeted protein degradation medicines, Nurix uses its 10-K, 10-Q and 8-K reports to describe pipeline progress, financing activities, collaborations and governance matters.
Recent Form 8-K filings illustrate the types of information NRIX investors can monitor here. One 8-K details an underwriting agreement for a registered offering of common stock under a shelf registration statement, including intended uses of proceeds such as funding clinical development of the BTK degrader bexobrutideg in chronic lymphocytic leukemia, exploring autoimmune indications, expanding the research pipeline and supporting general corporate purposes. Other 8-Ks report on the initiation of the pivotal DAYBreak Phase 2 study of bexobrutideg in relapsed or refractory CLL/SLL, updated clinical data for NX-1607, and changes to the board of directors and committee roles.
Through this page, users can review current and historical SEC documents related to Nurix’s common stock listed on the Nasdaq Global Market under the symbol NRIX. Filings may cover topics such as results of operations, equity offerings, clinical development milestones, collaboration agreements with partners like Gilead, Sanofi and Pfizer, and appointments or resignations of directors and officers.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand material events without reading every page. Real-time updates from EDGAR ensure that new 8-K, 10-Q, 10-K and other forms appear promptly, while dedicated sections make it easier to locate items related to capital raises, clinical trial disclosures or governance changes. For those tracking insider activity, Form 4 and related ownership filings can also be accessed to see how Nurix’s insiders transact in NRIX shares.
Christine Ring reported a Form 144 covering 8,148 common shares issuable from Restricted Stock Units dated 05/02/2022, to be sold through Morgan Stanley Smith Barney LLC. The filing lists multiple recent 10b5-1 sales by Ms. Ring on 12/18/2025, 01/20/2026, and 02/09/2026, with per-trade proceeds shown.
Nurix Therapeutics, Inc. is the subject of an amended Schedule 13G filing by Baker Bros. entities reporting a significant ownership position. The reporting group discloses beneficial ownership of 7,527,996 shares of Nurix common stock, representing 7.2% of the class, as of an outstanding share count of 101,807,484 shares on November 30, 2025.
The position includes 4,658,556 shares of common stock plus 2,869,440 additional shares issuable upon exercise of pre-funded warrants with a $0.001 exercise price. These pre-funded warrants are generally limited by a 9.99% beneficial ownership cap, which the funds may adjust up to 19.99% effective on the 61st day after written notice to the issuer.
Within the Baker Bros. complex, 667, L.P. holds 393,250 shares and 248,551 warrant shares, while Baker Brothers Life Sciences, L.P. holds 4,265,306 shares and 2,620,889 warrant shares, all subject to the ownership cap. Baker Bros. Advisors LP exercises investment and voting discretion for the funds and is reporting on a passive, non-control basis under Schedule 13G.
Nurix Therapeutics Chief Financial Officer Hans van Houte received new equity awards in the form of stock options and restricted stock units. On February 10, 2026, he was granted an employee stock option for 93,750 shares of common stock at an exercise price of $16.45 per share, vesting in equal monthly installments over three years until February 9, 2029, while he continues serving the company.
He was also granted 42,875 restricted stock units, each representing one share of common stock. These RSUs vest in equal quarterly installments over three years, with the first portion vesting on July 30, 2026, contingent on his continued service; vested shares will be delivered after each vesting date.
Nurix Therapeutics Chief Legal Officer receives new equity awards. On February 10, 2026, Christine Ring was granted an employee stock option for 93,750 shares of common stock at an exercise price of $16.45 per share and 42,875 restricted stock units.
The stock option vests in equal monthly installments over 36 months beginning March 10, 2026, and is fully vested by February 9, 2029, contingent on continued service. The RSUs vest in 12 quarterly installments over three years starting July 30, 2026, with one share of common stock delivered for each vested unit.
Nurix Therapeutics, Inc. reported that Chief Scientific Officer Gwenn Hansen received new equity awards on February 10, 2026. She was granted an option to buy 93,750 shares of common stock at $16.45 per share, vesting monthly over three years through February 9, 2029, subject to continued service.
Hansen was also granted 42,875 restricted stock units, each representing one share of common stock. These RSUs vest in 12 equal quarterly installments over three years, beginning July 30, 2026, with shares delivered after each vesting date as long as she remains in service.
Nurix Therapeutics President and CEO Arthur T. Sands received an employee stock option grant covering 562,500 shares of common stock at an exercise price of $16.45 per share on February 10, 2026.
The option vests in 36 equal monthly installments beginning March 10, 2026, and becomes fully vested on February 9, 2029, subject to his continued service. It is scheduled to expire on February 9, 2036.
Nurix Therapeutics’ Chief Legal Officer, Christine Ring, reported a planned sale of company stock. On 02/09/2026 she sold 14,261 shares of Nurix common stock at a weighted average price of $16.6621 per share under a pre‑arranged Rule 10b5‑1 trading plan. Following this sale, she beneficially owns 42,749 shares of Nurix common stock directly.
A shareholder of NRIX has filed a Rule 144 notice to sell 14,261 common shares, with an aggregate market value of $240,297.85, through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of 02/09/2026.
The shares were acquired as restricted stock units from the issuer on 05/02/2022. The filing also notes prior sales under a Rule 10b5-1 plan, including 3,760 shares sold on 01/20/2026 for $69,273.11 and 37,600 shares sold on 11/24/2025 for $641,697.02. Shares outstanding were 102,843,012 at the time referenced.
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported an option exercise and corresponding stock acquisition. On 02/03/2026, Hansen exercised an employee stock option for 31,333 shares of common stock at $0.84 per share, converting the derivative position to common stock. Following this transaction, Hansen directly beneficially owns 115,005 shares of Nurix common stock, and the reported option grant is fully vested with 0 derivative securities remaining.
Nurix Therapeutics, Inc.’s Chief Financial Officer, Hans van Houte, reported routine equity compensation activity and related tax sales. On January 30, 2026, several blocks of restricted stock units (RSUs) converted into common stock at $0 exercise price, including 2,887, 2,000, 3,750 and 2,859 RSUs.
To cover tax withholding from these RSU vestings, the CFO sold 3,588 shares at a weighted average price of $16.5826 and 73 shares at a weighted average price of $17.3717. The filing states these are mandatory “sell to cover” transactions, not discretionary trades. After the transactions, he directly owned 45,427 common shares and 25,725 RSUs.